th DC-CIK can significantly enhance the cellular immunity, improve the long-term survival rate and raise the quality of life of LANSCLC patients, with tolerable adverse reactions. Lycopsamine is an active pyrrolizidine alkaloid that shows significant bioactivity. Herein, lycopsamine was evaluated for the first time for its anti-lung cancer activity. Its effects on cellular apoptosis, autophagy, cell cycle and IL-2 gene were also examined. The human lung cancer A549 and normal MRC5 cells were used in the study. MTT assay was used to determine the cytotoxicity of lycopsamine. Transmission electron microscopy (TEM) and western blotting were implemented for analyzing autophagy. selleck DAPI staining, Annexin V/FITC/Propidium iodide (PI) and western blotting assays were used to study cellular apoptosis. Cell cycle was examined through flow cytometry. The expression of IL-2 gene was monitored by western blotting. Lycopsamine targeted the proliferation rate and reduced it remarkably in a dose-dependent manner. On searching for underlying mechanism, the antiproliferative effect of lycopsamine was due to autophagy and the expressions of pro-autophagy proteins (LC3-I, LC3-II, Beclin-1) increased on drug exposure. Furthermore, the antiproliferative effects were also found to be mediated via apoptosis induction and were associated with increased Bax and decreased Bcl-2 levels. Next, flow cytometry showed that lycopsamine inhibited cell cycle progression at G2/M-check point in lung cancer cells. Furthermore, the expressions of IL-2 gene decreased after lycopsamine treatment of these cells. In conclusion, on testifying the current designed hypothesis, lycopsamine showed significant antiproliferative effects in A549 lung cancer cells in a dose reliant manner. The antiproliferative effects of lycopsamine were associated with its autophagy inducing, apoptosis inducing, and inhibiting IL-2 expression, potential. Taken together, lycopsamine is a potent anti-lung cancer agent and can be a lead molecule in lung cancer treatment.Taken together, lycopsamine is a potent anti-lung cancer agent and can be a lead molecule in lung cancer treatment. This study aimed to compare eukaryotic translation initiation factor 3B (EIF3B) expression between tumor tissues and non-cancerous tissues and to investigate the correlation of tumor EIF3B with clinical characteristics and prognosis in non-small cell lung cancer (NSCLC) patients. The tumor samples and non-cancerous adjacent tissues of 365 operated NSCLC patients were acquired. The EIF3B expression in tumor tissues and non-cancerous tissues was detected by immunohistochemistry and was classified into four groups according to multiple staining intensity and staining density as follows; low EIF3B, high(+)EIF3B, high(++) EIF3B, and high(+++) EIF3B. The clinical characteristics were extracted from the database. The disease-free survival (DFS) and overall survival (OS) was calculated from the survival data. EIF3B was increased in tumor tissues (10.1% in high(+++) EIF3B, 17.5% in high(++) EIF3B, 29.9% in high(+) EIF3B, and 42.5% in low EIF3B group) compared to non-cancer tissues (2.2% in high(+++) EIF3B, 9.6% in high(++) EIF3B, 23.3% in high(+) EIF3B, and 64.9% in low EIF3B group) (p<0.001). Correlation analysis showed that tumor with higher EIF3B expression was correlated with the presence of lymph node metastasis (p=0.001) and more advanced TNM stage (p=0.026). Kaplan-Meier curves revealed that DFS and OS were worst in patients with high (+++) EIF3B expression (p<0.001). Notably, multivariate Cox's regression showed that a higher EIF3B expression was an independent predictive of decreased DFS (p=0.041) and OS (p=0.006). EIF3B might be a potential biomarker to improve the monitoring and management of NSCLC in clinical practice.EIF3B might be a potential biomarker to improve the monitoring and management of NSCLC in clinical practice. In this study we compared postoperative early vs sandwich chemoradiotherapy in operated stage IIA-IIIC gastric cancer patients in terms of effectiveness and outcome. The data of 201 gastric cancer patients treated in the same center between December 2006 and June 2017 were retrospectively evaluated. One hundred forty nine patients who were eligible for the study criteria were divided into two groups according to the postoperative treatment modality. The first group included 85 patients who were given chemoradiotherapy simultaneously (ETG) and the second group icluded 64 patients who received sandwich (chemotherapy-chemoradiotherapy-chemotherapy) (STG) treatment. Overall survival (OS) and disease-free survival (DFS) were evaluated as primary endpoints. The median follow-up time for all patient groups was 26.7 months (1.3 -136.5 months). Adjuvant chemotherapy and radiotherapy were initiated concurrently in patients receiving concomitant therapy. Half of the planned chemotherapy, then chemoradiotherapy andthe groups in terms of gender, T stage, N stage, and AJCC stage. In this study, superiority of sandwich treatment over concurrent treatment was observed in patients with operated stage IIB-IIIC gastric cancer, but the difference was not statistically significant. If this study is performed in larger patient series, the difference of sandwich treatment may become meaningful.In this study, superiority of sandwich treatment over concurrent treatment was observed in patients with operated stage IIB-IIIC gastric cancer, but the difference was not statistically significant. If this study is performed in larger patient series, the difference of sandwich treatment may become meaningful. To explore miR-195-5p expression and prognostic value in advanced gastric cancer (AGC) patients after chemotherapy. 114 patients in total with AGC admitted to our hospital undergoing chemotherapy created the gastric cancer group, and 100 simultaneous healthy subjects undergoing physical examination created the normal group. MiR-195-5p level in both groups was detected. miR-195-5p level was evidently lower in the gastric cancer group, and miR-195-5p could be used in diagnosing gastric cancer patients. miR-195-5p was significantly associated with clinical stage and grade of differentiation. It was found that carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) were significantly negatively associated with miR-195-5p level before treatment in patients with AGC. Subjects were divided into effective group and ineffective group based on the therapeutic effect, mir-195-5p level in the ineffective group was notably lower than that in the effective group, and the serum miR-195-5p level was available for efficacy prediction.